This year, technology transfer professionals and scientists representing 24 research institutes and universities in 14 European countries presented 40 commercial opportunities. These ranged from potential therapeutics and diagnostics to platform technologies. In addition, business developers from Bayer Pharma, Novo Nordisk, MSD and Boehringer Ingelheim presented their inlicensing needs. Altogether, about 170 delegates attended.
This year also saw a Spin-off Panel featuring six selected start-ups. Based on brief introductory statements and a challenging question time, a jury of seasoned life-science managers selected the most convincing candidate in terms of team, technology and business concept. This year’s winner of the BioVaria Spin-off Award is NdL, a start-up developing unique therapeutic nanoparticles for the treatment of autoimmune diseases. The prize is worth EUR 1,000 plus professional legal consulting. The second prize, a legal consulting package, went to MetaHeps, a Munich-based start-up offering dedicated services for evaluating the potential toxic effects of new medicines on liver tissue and function.